drugset / Trial / NCT01117051

Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation

NCT01117051

Phase 3 Terminated 174 enrolled Shire
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will evaluate the efficacy, safety and tolerability of prucalopride over 12 weeks of treatment in subjects aged 18 years and older with chronic non-cancer pain, suffering from opioid induced constipation.

Timeline

Start
2010-05-19
Primary completion
2012-08-13
Completion
2012-08-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 1 mg
Comparator Prucalopride Small molecule 2 mg